nodes	percent_of_prediction	percent_of_DWPC	metapath
Mianserin—HTR2B—Sorafenib—kidney cancer	0.0864	0.142	CbGbCtD
Mianserin—HTR2C—Sorafenib—kidney cancer	0.0562	0.0927	CbGbCtD
Mianserin—CYP2D6—Temsirolimus—kidney cancer	0.0553	0.0912	CbGbCtD
Mianserin—CYP3A4—Everolimus—kidney cancer	0.0521	0.0859	CbGbCtD
Mianserin—CYP1A2—Pazopanib—kidney cancer	0.0353	0.0582	CbGbCtD
Mianserin—CYP3A4—Temsirolimus—kidney cancer	0.0352	0.058	CbGbCtD
Mianserin—CYP2B6—Sorafenib—kidney cancer	0.0349	0.0576	CbGbCtD
Mianserin—CYP2D6—Pazopanib—kidney cancer	0.029	0.0479	CbGbCtD
Mianserin—CYP1A2—Erlotinib—kidney cancer	0.0252	0.0415	CbGbCtD
Mianserin—CYP2B6—Doxorubicin—kidney cancer	0.0212	0.0349	CbGbCtD
Mianserin—CYP2D6—Erlotinib—kidney cancer	0.0207	0.0342	CbGbCtD
Mianserin—CYP1A2—Sorafenib—kidney cancer	0.0205	0.0337	CbGbCtD
Mianserin—CYP3A4—Pazopanib—kidney cancer	0.0185	0.0305	CbGbCtD
Mianserin—CYP2D6—Sorafenib—kidney cancer	0.0169	0.0278	CbGbCtD
Mianserin—CYP2D6—Vinblastine—kidney cancer	0.0166	0.0275	CbGbCtD
Mianserin—CYP3A4—Erlotinib—kidney cancer	0.0132	0.0217	CbGbCtD
Mianserin—CYP3A4—Paclitaxel—kidney cancer	0.0121	0.0199	CbGbCtD
Mianserin—CYP3A4—Sorafenib—kidney cancer	0.0107	0.0177	CbGbCtD
Mianserin—CYP3A4—Vinblastine—kidney cancer	0.0106	0.0175	CbGbCtD
Mianserin—CYP3A4—Vincristine—kidney cancer	0.0104	0.0172	CbGbCtD
Mianserin—CYP2D6—Doxorubicin—kidney cancer	0.0102	0.0169	CbGbCtD
Mianserin—CYP3A4—Sunitinib—kidney cancer	0.00868	0.0143	CbGbCtD
Mianserin—CYP3A4—Doxorubicin—kidney cancer	0.0065	0.0107	CbGbCtD
Mianserin—CYP1A2—urine—kidney cancer	0.00151	0.0965	CbGeAlD
Mianserin—HTR2A—urine—kidney cancer	0.00118	0.0754	CbGeAlD
Mianserin—CYP3A4—urine—kidney cancer	0.0011	0.0698	CbGeAlD
Mianserin—CYP2D6—urine—kidney cancer	0.00108	0.0687	CbGeAlD
Mianserin—HRH2—cardiac atrium—kidney cancer	0.000818	0.0521	CbGeAlD
Mianserin—HTR1D—kidney—kidney cancer	0.000564	0.0359	CbGeAlD
Mianserin—Dermatitis—Temsirolimus—kidney cancer	0.000537	0.00186	CcSEcCtD
Mianserin—Breast disorder—Capecitabine—kidney cancer	0.000537	0.00186	CcSEcCtD
Mianserin—Skin disorder—Sorafenib—kidney cancer	0.000535	0.00185	CcSEcCtD
Mianserin—Headache—Temsirolimus—kidney cancer	0.000534	0.00185	CcSEcCtD
Mianserin—Dizziness—Pazopanib—kidney cancer	0.000531	0.00184	CcSEcCtD
Mianserin—Oedema—Sunitinib—kidney cancer	0.00053	0.00183	CcSEcCtD
Mianserin—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000528	0.00183	CcSEcCtD
Mianserin—Hepatobiliary disease—Paclitaxel—kidney cancer	0.000528	0.00183	CcSEcCtD
Mianserin—Fatigue—Erlotinib—kidney cancer	0.000527	0.00183	CcSEcCtD
Mianserin—Feeling abnormal—Vinblastine—kidney cancer	0.000524	0.00181	CcSEcCtD
Mianserin—Constipation—Erlotinib—kidney cancer	0.000523	0.00181	CcSEcCtD
Mianserin—Myalgia—Dactinomycin—kidney cancer	0.000523	0.00181	CcSEcCtD
Mianserin—Feeling abnormal—Everolimus—kidney cancer	0.000522	0.00181	CcSEcCtD
Mianserin—Shock—Sunitinib—kidney cancer	0.000521	0.0018	CcSEcCtD
Mianserin—Nervous system disorder—Sunitinib—kidney cancer	0.000519	0.0018	CcSEcCtD
Mianserin—Thrombocytopenia—Sunitinib—kidney cancer	0.000518	0.00179	CcSEcCtD
Mianserin—Skin disorder—Sunitinib—kidney cancer	0.000514	0.00178	CcSEcCtD
Mianserin—HTR2B—cortex of kidney—kidney cancer	0.000511	0.0325	CbGeAlD
Mianserin—Bradycardia—Paclitaxel—kidney cancer	0.00051	0.00176	CcSEcCtD
Mianserin—Anaemia—Vincristine—kidney cancer	0.000507	0.00176	CcSEcCtD
Mianserin—Rash—Pazopanib—kidney cancer	0.000506	0.00175	CcSEcCtD
Mianserin—Dermatitis—Pazopanib—kidney cancer	0.000506	0.00175	CcSEcCtD
Mianserin—Agitation—Vincristine—kidney cancer	0.000504	0.00175	CcSEcCtD
Mianserin—Headache—Pazopanib—kidney cancer	0.000503	0.00174	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Sorafenib—kidney cancer	0.000501	0.00174	CcSEcCtD
Mianserin—Oedema—Dactinomycin—kidney cancer	0.000501	0.00173	CcSEcCtD
Mianserin—Vertigo—Vincristine—kidney cancer	0.000493	0.00171	CcSEcCtD
Mianserin—Connective tissue disorder—Paclitaxel—kidney cancer	0.000492	0.0017	CcSEcCtD
Mianserin—Leukopenia—Vincristine—kidney cancer	0.000491	0.0017	CcSEcCtD
Mianserin—Thrombocytopenia—Dactinomycin—kidney cancer	0.000491	0.0017	CcSEcCtD
Mianserin—Pancytopenia—Capecitabine—kidney cancer	0.000488	0.00169	CcSEcCtD
Mianserin—HTR1A—renal system—kidney cancer	0.000486	0.031	CbGeAlD
Mianserin—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.000482	0.00167	CcSEcCtD
Mianserin—Anaemia—Gemcitabine—kidney cancer	0.000481	0.00167	CcSEcCtD
Mianserin—Neutropenia—Capecitabine—kidney cancer	0.00048	0.00166	CcSEcCtD
Mianserin—Paraesthesia—Sunitinib—kidney cancer	0.000475	0.00165	CcSEcCtD
Mianserin—Convulsion—Vincristine—kidney cancer	0.000475	0.00165	CcSEcCtD
Mianserin—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000475	0.00164	CcSEcCtD
Mianserin—Fatigue—Sorafenib—kidney cancer	0.000474	0.00164	CcSEcCtD
Mianserin—Hypertension—Vincristine—kidney cancer	0.000474	0.00164	CcSEcCtD
Mianserin—Constipation—Sorafenib—kidney cancer	0.000471	0.00163	CcSEcCtD
Mianserin—ADRA2C—nephron tubule—kidney cancer	0.00047	0.0299	CbGeAlD
Mianserin—Eye disorder—Paclitaxel—kidney cancer	0.000468	0.00162	CcSEcCtD
Mianserin—Myalgia—Vincristine—kidney cancer	0.000467	0.00162	CcSEcCtD
Mianserin—Weight increased—Capecitabine—kidney cancer	0.000467	0.00162	CcSEcCtD
Mianserin—Tinnitus—Paclitaxel—kidney cancer	0.000467	0.00162	CcSEcCtD
Mianserin—Leukopenia—Gemcitabine—kidney cancer	0.000466	0.00161	CcSEcCtD
Mianserin—Cardiac disorder—Paclitaxel—kidney cancer	0.000465	0.00161	CcSEcCtD
Mianserin—HTR7—renal system—kidney cancer	0.000465	0.0296	CbGeAlD
Mianserin—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000457	0.00158	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.000457	0.00158	CcSEcCtD
Mianserin—Asthenia—Vinblastine—kidney cancer	0.000457	0.00158	CcSEcCtD
Mianserin—Fatigue—Sunitinib—kidney cancer	0.000457	0.00158	CcSEcCtD
Mianserin—Asthenia—Everolimus—kidney cancer	0.000455	0.00157	CcSEcCtD
Mianserin—Angiopathy—Paclitaxel—kidney cancer	0.000454	0.00157	CcSEcCtD
Mianserin—Constipation—Sunitinib—kidney cancer	0.000453	0.00157	CcSEcCtD
Mianserin—Mediastinal disorder—Paclitaxel—kidney cancer	0.000451	0.00156	CcSEcCtD
Mianserin—Hypertension—Gemcitabine—kidney cancer	0.000449	0.00156	CcSEcCtD
Mianserin—HTR7—kidney—kidney cancer	0.000449	0.0286	CbGeAlD
Mianserin—Pruritus—Everolimus—kidney cancer	0.000449	0.00155	CcSEcCtD
Mianserin—Oedema—Vincristine—kidney cancer	0.000448	0.00155	CcSEcCtD
Mianserin—Jaundice—Capecitabine—kidney cancer	0.000446	0.00154	CcSEcCtD
Mianserin—Myalgia—Gemcitabine—kidney cancer	0.000443	0.00153	CcSEcCtD
Mianserin—Arthralgia—Gemcitabine—kidney cancer	0.000443	0.00153	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.00044	0.00152	CcSEcCtD
Mianserin—Nervous system disorder—Vincristine—kidney cancer	0.000439	0.00152	CcSEcCtD
Mianserin—Asthenia—Erlotinib—kidney cancer	0.000439	0.00152	CcSEcCtD
Mianserin—Mental disorder—Paclitaxel—kidney cancer	0.000439	0.00152	CcSEcCtD
Mianserin—Thrombocytopenia—Vincristine—kidney cancer	0.000439	0.00152	CcSEcCtD
Mianserin—Hepatic function abnormal—Doxorubicin—kidney cancer	0.000438	0.00152	CcSEcCtD
Mianserin—Hepatobiliary disease—Capecitabine—kidney cancer	0.000433	0.0015	CcSEcCtD
Mianserin—Pruritus—Erlotinib—kidney cancer	0.000433	0.0015	CcSEcCtD
Mianserin—SLC6A2—gonad—kidney cancer	0.000432	0.0275	CbGeAlD
Mianserin—Fatigue—Dactinomycin—kidney cancer	0.000432	0.0015	CcSEcCtD
Mianserin—Agranulocytosis—Capecitabine—kidney cancer	0.000427	0.00148	CcSEcCtD
Mianserin—ADRA2C—renal system—kidney cancer	0.000427	0.0272	CbGeAlD
Mianserin—Oedema—Gemcitabine—kidney cancer	0.000425	0.00147	CcSEcCtD
Mianserin—Dizziness—Vinblastine—kidney cancer	0.000421	0.00146	CcSEcCtD
Mianserin—Dizziness—Everolimus—kidney cancer	0.000419	0.00145	CcSEcCtD
Mianserin—Hypotension—Vincristine—kidney cancer	0.000419	0.00145	CcSEcCtD
Mianserin—Bradycardia—Capecitabine—kidney cancer	0.000418	0.00145	CcSEcCtD
Mianserin—Nervous system disorder—Gemcitabine—kidney cancer	0.000417	0.00144	CcSEcCtD
Mianserin—HTR7—gonad—kidney cancer	0.000417	0.0265	CbGeAlD
Mianserin—Thrombocytopenia—Gemcitabine—kidney cancer	0.000416	0.00144	CcSEcCtD
Mianserin—Feeling abnormal—Dactinomycin—kidney cancer	0.000413	0.00143	CcSEcCtD
Mianserin—ADRA2C—kidney—kidney cancer	0.000413	0.0263	CbGeAlD
Mianserin—Skin disorder—Gemcitabine—kidney cancer	0.000413	0.00143	CcSEcCtD
Mianserin—Hepatitis—Capecitabine—kidney cancer	0.000411	0.00142	CcSEcCtD
Mianserin—Tremor—Paclitaxel—kidney cancer	0.000408	0.00141	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000408	0.00141	CcSEcCtD
Mianserin—Dizziness—Erlotinib—kidney cancer	0.000404	0.0014	CcSEcCtD
Mianserin—Connective tissue disorder—Capecitabine—kidney cancer	0.000404	0.0014	CcSEcCtD
Mianserin—Anaemia—Paclitaxel—kidney cancer	0.000403	0.00139	CcSEcCtD
Mianserin—Paraesthesia—Vincristine—kidney cancer	0.000402	0.00139	CcSEcCtD
Mianserin—ADRA2C—cortex of kidney—kidney cancer	0.000402	0.0256	CbGeAlD
Mianserin—Agitation—Paclitaxel—kidney cancer	0.000401	0.00139	CcSEcCtD
Mianserin—Rash—Everolimus—kidney cancer	0.0004	0.00138	CcSEcCtD
Mianserin—Dermatitis—Everolimus—kidney cancer	0.000399	0.00138	CcSEcCtD
Mianserin—Headache—Vinblastine—kidney cancer	0.000399	0.00138	CcSEcCtD
Mianserin—Headache—Everolimus—kidney cancer	0.000397	0.00137	CcSEcCtD
Mianserin—Hypotension—Gemcitabine—kidney cancer	0.000397	0.00137	CcSEcCtD
Mianserin—Asthenia—Sorafenib—kidney cancer	0.000395	0.00137	CcSEcCtD
Mianserin—Cardiac failure—Doxorubicin—kidney cancer	0.000392	0.00136	CcSEcCtD
Mianserin—Vertigo—Paclitaxel—kidney cancer	0.000392	0.00136	CcSEcCtD
Mianserin—Syncope—Paclitaxel—kidney cancer	0.000391	0.00135	CcSEcCtD
Mianserin—Lethargy—Doxorubicin—kidney cancer	0.000391	0.00135	CcSEcCtD
Mianserin—CYP2B6—nephron tubule—kidney cancer	0.000391	0.0249	CbGeAlD
Mianserin—Leukopenia—Paclitaxel—kidney cancer	0.00039	0.00135	CcSEcCtD
Mianserin—Pruritus—Sorafenib—kidney cancer	0.000389	0.00135	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000387	0.00134	CcSEcCtD
Mianserin—Gastrointestinal disorder—Vincristine—kidney cancer	0.000387	0.00134	CcSEcCtD
Mianserin—Fatigue—Vincristine—kidney cancer	0.000386	0.00134	CcSEcCtD
Mianserin—Rash—Erlotinib—kidney cancer	0.000386	0.00133	CcSEcCtD
Mianserin—Dermatitis—Erlotinib—kidney cancer	0.000385	0.00133	CcSEcCtD
Mianserin—Eye disorder—Capecitabine—kidney cancer	0.000384	0.00133	CcSEcCtD
Mianserin—Headache—Erlotinib—kidney cancer	0.000383	0.00133	CcSEcCtD
Mianserin—Tinnitus—Capecitabine—kidney cancer	0.000383	0.00133	CcSEcCtD
Mianserin—Loss of consciousness—Paclitaxel—kidney cancer	0.000383	0.00133	CcSEcCtD
Mianserin—Constipation—Vincristine—kidney cancer	0.000383	0.00133	CcSEcCtD
Mianserin—Diplopia—Doxorubicin—kidney cancer	0.000383	0.00133	CcSEcCtD
Mianserin—ADRA2C—cardiac atrium—kidney cancer	0.000382	0.0244	CbGeAlD
Mianserin—Paraesthesia—Gemcitabine—kidney cancer	0.000382	0.00132	CcSEcCtD
Mianserin—Cardiac disorder—Capecitabine—kidney cancer	0.000381	0.00132	CcSEcCtD
Mianserin—Asthenia—Sunitinib—kidney cancer	0.00038	0.00131	CcSEcCtD
Mianserin—Somnolence—Gemcitabine—kidney cancer	0.000378	0.00131	CcSEcCtD
Mianserin—Convulsion—Paclitaxel—kidney cancer	0.000378	0.00131	CcSEcCtD
Mianserin—Hypertension—Paclitaxel—kidney cancer	0.000376	0.0013	CcSEcCtD
Mianserin—Pruritus—Sunitinib—kidney cancer	0.000375	0.0013	CcSEcCtD
Mianserin—Angiopathy—Capecitabine—kidney cancer	0.000373	0.00129	CcSEcCtD
Mianserin—Myalgia—Paclitaxel—kidney cancer	0.000371	0.00128	CcSEcCtD
Mianserin—Arthralgia—Paclitaxel—kidney cancer	0.000371	0.00128	CcSEcCtD
Mianserin—CYP1A2—renal system—kidney cancer	0.000371	0.0236	CbGeAlD
Mianserin—Mediastinal disorder—Capecitabine—kidney cancer	0.00037	0.00128	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000369	0.00128	CcSEcCtD
Mianserin—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000367	0.00127	CcSEcCtD
Mianserin—Fatigue—Gemcitabine—kidney cancer	0.000366	0.00127	CcSEcCtD
Mianserin—Cardiac arrest—Doxorubicin—kidney cancer	0.000364	0.00126	CcSEcCtD
Mianserin—Dizziness—Sorafenib—kidney cancer	0.000364	0.00126	CcSEcCtD
Mianserin—Constipation—Gemcitabine—kidney cancer	0.000363	0.00126	CcSEcCtD
Mianserin—Dry mouth—Paclitaxel—kidney cancer	0.000363	0.00126	CcSEcCtD
Mianserin—Mental disorder—Capecitabine—kidney cancer	0.00036	0.00125	CcSEcCtD
Mianserin—Asthenia—Dactinomycin—kidney cancer	0.00036	0.00124	CcSEcCtD
Mianserin—Confusional state—Paclitaxel—kidney cancer	0.000359	0.00124	CcSEcCtD
Mianserin—Oedema—Paclitaxel—kidney cancer	0.000356	0.00123	CcSEcCtD
Mianserin—CYP2B6—renal system—kidney cancer	0.000355	0.0226	CbGeAlD
Mianserin—Dizziness—Sunitinib—kidney cancer	0.00035	0.00121	CcSEcCtD
Mianserin—Feeling abnormal—Gemcitabine—kidney cancer	0.00035	0.00121	CcSEcCtD
Mianserin—Shock—Paclitaxel—kidney cancer	0.00035	0.00121	CcSEcCtD
Mianserin—Nervous system disorder—Paclitaxel—kidney cancer	0.000349	0.00121	CcSEcCtD
Mianserin—Thrombocytopenia—Paclitaxel—kidney cancer	0.000348	0.00121	CcSEcCtD
Mianserin—Tachycardia—Paclitaxel—kidney cancer	0.000347	0.0012	CcSEcCtD
Mianserin—Rash—Sorafenib—kidney cancer	0.000347	0.0012	CcSEcCtD
Mianserin—Dermatitis—Sorafenib—kidney cancer	0.000347	0.0012	CcSEcCtD
Mianserin—Breast disorder—Doxorubicin—kidney cancer	0.000346	0.0012	CcSEcCtD
Mianserin—Skin disorder—Paclitaxel—kidney cancer	0.000346	0.0012	CcSEcCtD
Mianserin—Headache—Sorafenib—kidney cancer	0.000345	0.00119	CcSEcCtD
Mianserin—CYP2B6—kidney—kidney cancer	0.000343	0.0219	CbGeAlD
Mianserin—Tremor—Capecitabine—kidney cancer	0.000335	0.00116	CcSEcCtD
Mianserin—Rash—Sunitinib—kidney cancer	0.000334	0.00116	CcSEcCtD
Mianserin—Dermatitis—Sunitinib—kidney cancer	0.000334	0.00115	CcSEcCtD
Mianserin—Hypotension—Paclitaxel—kidney cancer	0.000332	0.00115	CcSEcCtD
Mianserin—Headache—Sunitinib—kidney cancer	0.000332	0.00115	CcSEcCtD
Mianserin—Anaemia—Capecitabine—kidney cancer	0.000331	0.00114	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000324	0.00112	CcSEcCtD
Mianserin—Vertigo—Capecitabine—kidney cancer	0.000321	0.00111	CcSEcCtD
Mianserin—Asthenia—Vincristine—kidney cancer	0.000321	0.00111	CcSEcCtD
Mianserin—Syncope—Capecitabine—kidney cancer	0.000321	0.00111	CcSEcCtD
Mianserin—ADRA2A—cortex of kidney—kidney cancer	0.000321	0.0204	CbGeAlD
Mianserin—Leukopenia—Capecitabine—kidney cancer	0.00032	0.00111	CcSEcCtD
Mianserin—Paraesthesia—Paclitaxel—kidney cancer	0.000319	0.00111	CcSEcCtD
Mianserin—CYP2B6—gonad—kidney cancer	0.000318	0.0203	CbGeAlD
Mianserin—Somnolence—Paclitaxel—kidney cancer	0.000316	0.00109	CcSEcCtD
Mianserin—Rash—Dactinomycin—kidney cancer	0.000316	0.00109	CcSEcCtD
Mianserin—Loss of consciousness—Capecitabine—kidney cancer	0.000314	0.00109	CcSEcCtD
Mianserin—Pancytopenia—Doxorubicin—kidney cancer	0.000314	0.00109	CcSEcCtD
Mianserin—Neutropenia—Doxorubicin—kidney cancer	0.000309	0.00107	CcSEcCtD
Mianserin—Hypertension—Capecitabine—kidney cancer	0.000309	0.00107	CcSEcCtD
Mianserin—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000307	0.00106	CcSEcCtD
Mianserin—Fatigue—Paclitaxel—kidney cancer	0.000307	0.00106	CcSEcCtD
Mianserin—ADRA2A—gonad—kidney cancer	0.000306	0.0195	CbGeAlD
Mianserin—ADRA2A—cardiac atrium—kidney cancer	0.000305	0.0194	CbGeAlD
Mianserin—Asthenia—Gemcitabine—kidney cancer	0.000305	0.00106	CcSEcCtD
Mianserin—Myalgia—Capecitabine—kidney cancer	0.000305	0.00105	CcSEcCtD
Mianserin—Arthralgia—Capecitabine—kidney cancer	0.000305	0.00105	CcSEcCtD
Mianserin—Constipation—Paclitaxel—kidney cancer	0.000304	0.00105	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000302	0.00105	CcSEcCtD
Mianserin—Weight increased—Doxorubicin—kidney cancer	0.000301	0.00104	CcSEcCtD
Mianserin—Pruritus—Gemcitabine—kidney cancer	0.000301	0.00104	CcSEcCtD
Mianserin—Dry mouth—Capecitabine—kidney cancer	0.000298	0.00103	CcSEcCtD
Mianserin—Dizziness—Vincristine—kidney cancer	0.000296	0.00103	CcSEcCtD
Mianserin—Drowsiness—Doxorubicin—kidney cancer	0.000295	0.00102	CcSEcCtD
Mianserin—Confusional state—Capecitabine—kidney cancer	0.000294	0.00102	CcSEcCtD
Mianserin—Feeling abnormal—Paclitaxel—kidney cancer	0.000293	0.00101	CcSEcCtD
Mianserin—Oedema—Capecitabine—kidney cancer	0.000292	0.00101	CcSEcCtD
Mianserin—HTR2A—renal system—kidney cancer	0.00029	0.0185	CbGeAlD
Mianserin—Jaundice—Doxorubicin—kidney cancer	0.000288	0.000995	CcSEcCtD
Mianserin—Shock—Capecitabine—kidney cancer	0.000287	0.000994	CcSEcCtD
Mianserin—Nervous system disorder—Capecitabine—kidney cancer	0.000286	0.000991	CcSEcCtD
Mianserin—Thrombocytopenia—Capecitabine—kidney cancer	0.000286	0.000989	CcSEcCtD
Mianserin—Tachycardia—Capecitabine—kidney cancer	0.000285	0.000986	CcSEcCtD
Mianserin—Skin disorder—Capecitabine—kidney cancer	0.000284	0.000981	CcSEcCtD
Mianserin—Rash—Vincristine—kidney cancer	0.000282	0.000977	CcSEcCtD
Mianserin—Dermatitis—Vincristine—kidney cancer	0.000282	0.000976	CcSEcCtD
Mianserin—Headache—Vincristine—kidney cancer	0.000281	0.000971	CcSEcCtD
Mianserin—HTR2A—kidney—kidney cancer	0.00028	0.0178	CbGeAlD
Mianserin—Hepatobiliary disease—Doxorubicin—kidney cancer	0.000279	0.000966	CcSEcCtD
Mianserin—Agranulocytosis—Doxorubicin—kidney cancer	0.000275	0.000953	CcSEcCtD
Mianserin—Hypotension—Capecitabine—kidney cancer	0.000273	0.000944	CcSEcCtD
Mianserin—Bradycardia—Doxorubicin—kidney cancer	0.00027	0.000933	CcSEcCtD
Mianserin—CYP3A4—renal system—kidney cancer	0.000268	0.0171	CbGeAlD
Mianserin—Rash—Gemcitabine—kidney cancer	0.000268	0.000927	CcSEcCtD
Mianserin—Dermatitis—Gemcitabine—kidney cancer	0.000268	0.000926	CcSEcCtD
Mianserin—Headache—Gemcitabine—kidney cancer	0.000266	0.000921	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000266	0.00092	CcSEcCtD
Mianserin—Hepatitis—Doxorubicin—kidney cancer	0.000265	0.000917	CcSEcCtD
Mianserin—CYP2D6—renal system—kidney cancer	0.000264	0.0168	CbGeAlD
Mianserin—Paraesthesia—Capecitabine—kidney cancer	0.000262	0.000907	CcSEcCtD
Mianserin—Connective tissue disorder—Doxorubicin—kidney cancer	0.00026	0.000901	CcSEcCtD
Mianserin—HTR2A—gonad—kidney cancer	0.00026	0.0166	CbGeAlD
Mianserin—CYP3A4—kidney—kidney cancer	0.000259	0.0165	CbGeAlD
Mianserin—Asthenia—Paclitaxel—kidney cancer	0.000255	0.000883	CcSEcCtD
Mianserin—CYP2D6—kidney—kidney cancer	0.000255	0.0163	CbGeAlD
Mianserin—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000252	0.000872	CcSEcCtD
Mianserin—Fatigue—Capecitabine—kidney cancer	0.000252	0.000871	CcSEcCtD
Mianserin—Pruritus—Paclitaxel—kidney cancer	0.000252	0.000871	CcSEcCtD
Mianserin—Constipation—Capecitabine—kidney cancer	0.00025	0.000864	CcSEcCtD
Mianserin—Eye disorder—Doxorubicin—kidney cancer	0.000248	0.000857	CcSEcCtD
Mianserin—Tinnitus—Doxorubicin—kidney cancer	0.000247	0.000855	CcSEcCtD
Mianserin—Cardiac disorder—Doxorubicin—kidney cancer	0.000246	0.000851	CcSEcCtD
Mianserin—Feeling abnormal—Capecitabine—kidney cancer	0.000241	0.000833	CcSEcCtD
Mianserin—Angiopathy—Doxorubicin—kidney cancer	0.00024	0.000832	CcSEcCtD
Mianserin—Mediastinal disorder—Doxorubicin—kidney cancer	0.000239	0.000826	CcSEcCtD
Mianserin—Dizziness—Paclitaxel—kidney cancer	0.000235	0.000814	CcSEcCtD
Mianserin—Mental disorder—Doxorubicin—kidney cancer	0.000232	0.000803	CcSEcCtD
Mianserin—Rash—Paclitaxel—kidney cancer	0.000224	0.000776	CcSEcCtD
Mianserin—Dermatitis—Paclitaxel—kidney cancer	0.000224	0.000776	CcSEcCtD
Mianserin—Headache—Paclitaxel—kidney cancer	0.000223	0.000771	CcSEcCtD
Mianserin—Anaemia—Doxorubicin—kidney cancer	0.000213	0.000738	CcSEcCtD
Mianserin—Agitation—Doxorubicin—kidney cancer	0.000212	0.000733	CcSEcCtD
Mianserin—Asthenia—Capecitabine—kidney cancer	0.000209	0.000725	CcSEcCtD
Mianserin—Vertigo—Doxorubicin—kidney cancer	0.000207	0.000717	CcSEcCtD
Mianserin—Syncope—Doxorubicin—kidney cancer	0.000207	0.000716	CcSEcCtD
Mianserin—Pruritus—Capecitabine—kidney cancer	0.000207	0.000715	CcSEcCtD
Mianserin—Leukopenia—Doxorubicin—kidney cancer	0.000206	0.000714	CcSEcCtD
Mianserin—Loss of consciousness—Doxorubicin—kidney cancer	0.000203	0.000701	CcSEcCtD
Mianserin—Convulsion—Doxorubicin—kidney cancer	0.0002	0.000691	CcSEcCtD
Mianserin—Hypertension—Doxorubicin—kidney cancer	0.000199	0.000689	CcSEcCtD
Mianserin—Arthralgia—Doxorubicin—kidney cancer	0.000196	0.000679	CcSEcCtD
Mianserin—Myalgia—Doxorubicin—kidney cancer	0.000196	0.000679	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000195	0.000675	CcSEcCtD
Mianserin—Dizziness—Capecitabine—kidney cancer	0.000193	0.000668	CcSEcCtD
Mianserin—Dry mouth—Doxorubicin—kidney cancer	0.000192	0.000664	CcSEcCtD
Mianserin—Confusional state—Doxorubicin—kidney cancer	0.00019	0.000657	CcSEcCtD
Mianserin—Oedema—Doxorubicin—kidney cancer	0.000188	0.000651	CcSEcCtD
Mianserin—Shock—Doxorubicin—kidney cancer	0.000185	0.000641	CcSEcCtD
Mianserin—Nervous system disorder—Doxorubicin—kidney cancer	0.000185	0.000639	CcSEcCtD
Mianserin—Thrombocytopenia—Doxorubicin—kidney cancer	0.000184	0.000638	CcSEcCtD
Mianserin—Rash—Capecitabine—kidney cancer	0.000184	0.000637	CcSEcCtD
Mianserin—Dermatitis—Capecitabine—kidney cancer	0.000184	0.000636	CcSEcCtD
Mianserin—Tachycardia—Doxorubicin—kidney cancer	0.000184	0.000636	CcSEcCtD
Mianserin—Headache—Capecitabine—kidney cancer	0.000183	0.000633	CcSEcCtD
Mianserin—Skin disorder—Doxorubicin—kidney cancer	0.000183	0.000633	CcSEcCtD
Mianserin—Hypotension—Doxorubicin—kidney cancer	0.000176	0.000609	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000171	0.000593	CcSEcCtD
Mianserin—Paraesthesia—Doxorubicin—kidney cancer	0.000169	0.000585	CcSEcCtD
Mianserin—Somnolence—Doxorubicin—kidney cancer	0.000167	0.000579	CcSEcCtD
Mianserin—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000162	0.000562	CcSEcCtD
Mianserin—Fatigue—Doxorubicin—kidney cancer	0.000162	0.000561	CcSEcCtD
Mianserin—Constipation—Doxorubicin—kidney cancer	0.000161	0.000557	CcSEcCtD
Mianserin—Feeling abnormal—Doxorubicin—kidney cancer	0.000155	0.000537	CcSEcCtD
Mianserin—Asthenia—Doxorubicin—kidney cancer	0.000135	0.000467	CcSEcCtD
Mianserin—Pruritus—Doxorubicin—kidney cancer	0.000133	0.000461	CcSEcCtD
Mianserin—Dizziness—Doxorubicin—kidney cancer	0.000124	0.000431	CcSEcCtD
Mianserin—Rash—Doxorubicin—kidney cancer	0.000119	0.000411	CcSEcCtD
Mianserin—Dermatitis—Doxorubicin—kidney cancer	0.000119	0.00041	CcSEcCtD
Mianserin—Headache—Doxorubicin—kidney cancer	0.000118	0.000408	CcSEcCtD
Mianserin—HRH1—Signaling Pathways—POMC—kidney cancer	7.01e-06	7.86e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—VEGFA—kidney cancer	7e-06	7.85e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling by GPCR—PIK3CA—kidney cancer	7e-06	7.84e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—PTEN—kidney cancer	6.97e-06	7.82e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—RAF1—kidney cancer	6.94e-06	7.78e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—BRAF—kidney cancer	6.93e-06	7.77e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—BRAF—kidney cancer	6.92e-06	7.76e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—RELA—kidney cancer	6.91e-06	7.75e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—VEGFA—kidney cancer	6.9e-06	7.73e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—IL2—kidney cancer	6.9e-06	7.73e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—VEGFA—kidney cancer	6.89e-06	7.73e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—ERBB2—kidney cancer	6.87e-06	7.7e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—VEGFA—kidney cancer	6.85e-06	7.68e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—SCARB1—kidney cancer	6.84e-06	7.67e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—MAPK1—kidney cancer	6.83e-06	7.66e-05	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—TP53—kidney cancer	6.8e-06	7.62e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MTOR—kidney cancer	6.78e-06	7.6e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PTGS1—kidney cancer	6.78e-06	7.59e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling by GPCR—PIK3CA—kidney cancer	6.75e-06	7.57e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—MAPK1—kidney cancer	6.72e-06	7.54e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—CCND1—kidney cancer	6.72e-06	7.53e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling by GPCR—PIK3CA—kidney cancer	6.72e-06	7.53e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—KIT—kidney cancer	6.71e-06	7.52e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—APC—kidney cancer	6.71e-06	7.52e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—MAPK1—kidney cancer	6.71e-06	7.52e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—JUN—kidney cancer	6.71e-06	7.52e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—RAF1—kidney cancer	6.7e-06	7.51e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—CYP1A1—kidney cancer	6.68e-06	7.49e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—RELA—kidney cancer	6.67e-06	7.48e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—RAF1—kidney cancer	6.67e-06	7.47e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—CTNNB1—kidney cancer	6.66e-06	7.46e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PSMD7—kidney cancer	6.64e-06	7.45e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—RELA—kidney cancer	6.64e-06	7.44e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—ERBB2—kidney cancer	6.63e-06	7.43e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—MAPK3—kidney cancer	6.62e-06	7.42e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—ERBB2—kidney cancer	6.6e-06	7.39e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	6.59e-06	7.38e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MTOR—kidney cancer	6.54e-06	7.34e-05	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—PTEN—kidney cancer	6.54e-06	7.33e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling by GPCR—PIK3CA—kidney cancer	6.53e-06	7.32e-05	CbGpPWpGaD
Mianserin—DRD2—GPCR downstream signaling—PIK3CA—kidney cancer	6.53e-06	7.32e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—MAPK3—kidney cancer	6.53e-06	7.32e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—MAPK3—kidney cancer	6.52e-06	7.31e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MTOR—kidney cancer	6.51e-06	7.3e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—GSTP1—kidney cancer	6.49e-06	7.28e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—PTEN—kidney cancer	6.49e-06	7.27e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—RAF1—kidney cancer	6.49e-06	7.27e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—MAPK3—kidney cancer	6.48e-06	7.26e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—RELA—kidney cancer	6.46e-06	7.24e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—KRAS—kidney cancer	6.45e-06	7.23e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—MYC—kidney cancer	6.44e-06	7.22e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—MAPK3—kidney cancer	6.43e-06	7.21e-05	CbGpPWpGaD
Mianserin—HTR2A—GPCR downstream signaling—PIK3CA—kidney cancer	6.42e-06	7.2e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—ERBB2—kidney cancer	6.42e-06	7.19e-05	CbGpPWpGaD
Mianserin—HRH1—GPCR downstream signaling—PIK3CA—kidney cancer	6.41e-06	7.19e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—POMC—kidney cancer	6.39e-06	7.16e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—CDKN1B—kidney cancer	6.36e-06	7.13e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—KRAS—kidney cancer	6.35e-06	7.12e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—MYC—kidney cancer	6.35e-06	7.12e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—MYC—kidney cancer	6.34e-06	7.11e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—KRAS—kidney cancer	6.34e-06	7.1e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MTOR—kidney cancer	6.33e-06	7.1e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—BRAF—kidney cancer	6.31e-06	7.07e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—MAPK1—kidney cancer	6.3e-06	7.06e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—MYC—kidney cancer	6.3e-06	7.06e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—BCHE—kidney cancer	6.3e-06	7.06e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—VEGFA—kidney cancer	6.3e-06	7.06e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—IL2—kidney cancer	6.23e-06	6.98e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—SLC5A5—kidney cancer	6.22e-06	6.97e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—MAPK1—kidney cancer	6.21e-06	6.96e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—MAPK1—kidney cancer	6.2e-06	6.95e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—MAPK1—kidney cancer	6.16e-06	6.91e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—ABCB1—kidney cancer	6.15e-06	6.89e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—CDKN1B—kidney cancer	6.14e-06	6.88e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—MAPK1—kidney cancer	6.12e-06	6.86e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—CDKN1B—kidney cancer	6.11e-06	6.85e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—PTGS2—kidney cancer	6.09e-06	6.83e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—CCND1—kidney cancer	6.07e-06	6.8e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—JUN—kidney cancer	6.06e-06	6.79e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—CTNNB1—kidney cancer	6.01e-06	6.74e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—IL2—kidney cancer	6.01e-06	6.74e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—SLC2A1—kidney cancer	6.01e-06	6.74e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—IL2—kidney cancer	5.98e-06	6.7e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—GSTM1—kidney cancer	5.97e-06	6.69e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—MAPK3—kidney cancer	5.96e-06	6.68e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—KRAS—kidney cancer	5.95e-06	6.67e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—CDKN1B—kidney cancer	5.94e-06	6.66e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—PIK3CA—kidney cancer	5.93e-06	6.65e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—RAF1—kidney cancer	5.88e-06	6.6e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—KRAS—kidney cancer	5.87e-06	6.58e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—VEGFA—kidney cancer	5.86e-06	6.57e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—KRAS—kidney cancer	5.86e-06	6.57e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—RELA—kidney cancer	5.86e-06	6.57e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—CCND1—kidney cancer	5.86e-06	6.57e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—PTEN—kidney cancer	5.86e-06	6.57e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—JUN—kidney cancer	5.85e-06	6.55e-05	CbGpPWpGaD
Mianserin—ADRA2A—GPCR downstream signaling—PIK3CA—kidney cancer	5.84e-06	6.55e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—PIK3CA—kidney cancer	5.83e-06	6.54e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—CCND1—kidney cancer	5.83e-06	6.53e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—ERBB2—kidney cancer	5.82e-06	6.53e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—PIK3CA—kidney cancer	5.82e-06	6.53e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—KRAS—kidney cancer	5.82e-06	6.53e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—JUN—kidney cancer	5.82e-06	6.52e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—IL2—kidney cancer	5.82e-06	6.52e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—CTNNB1—kidney cancer	5.8e-06	6.5e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—MYC—kidney cancer	5.79e-06	6.5e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—RAF1—kidney cancer	5.79e-06	6.49e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—RAF1—kidney cancer	5.78e-06	6.48e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	5.78e-06	6.48e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	5.77e-06	6.47e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—RELA—kidney cancer	5.76e-06	6.46e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—RELA—kidney cancer	5.75e-06	6.45e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MTOR—kidney cancer	5.75e-06	6.44e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—ERBB2—kidney cancer	5.73e-06	6.42e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—ERBB2—kidney cancer	5.72e-06	6.41e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PTGS2—kidney cancer	5.71e-06	6.4e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—CCND1—kidney cancer	5.67e-06	6.35e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—MAPK1—kidney cancer	5.67e-06	6.35e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—CYP1A1—kidney cancer	5.66e-06	6.34e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—JUN—kidney cancer	5.66e-06	6.34e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—PTEN—kidney cancer	5.65e-06	6.34e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MTOR—kidney cancer	5.65e-06	6.34e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MTOR—kidney cancer	5.64e-06	6.32e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—PTEN—kidney cancer	5.63e-06	6.31e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—CTNNB1—kidney cancer	5.61e-06	6.29e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—MAPK3—kidney cancer	5.54e-06	6.21e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—PTEN—kidney cancer	5.47e-06	6.13e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—PIK3CA—kidney cancer	5.47e-06	6.13e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—MYC—kidney cancer	5.39e-06	6.04e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CDKN1B—kidney cancer	5.39e-06	6.04e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—PIK3CA—kidney cancer	5.39e-06	6.04e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—PIK3CA—kidney cancer	5.38e-06	6.03e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—KRAS—kidney cancer	5.35e-06	6e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—PIK3CA—kidney cancer	5.35e-06	5.99e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—PTEN—kidney cancer	5.31e-06	5.96e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	5.31e-06	5.95e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CDKN1B—kidney cancer	5.31e-06	5.95e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CDKN1B—kidney cancer	5.29e-06	5.93e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—VEGFA—kidney cancer	5.29e-06	5.93e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—TP53—kidney cancer	5.29e-06	5.93e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—IL2—kidney cancer	5.28e-06	5.91e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—MAPK1—kidney cancer	5.27e-06	5.91e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—RAF1—kidney cancer	5.27e-06	5.9e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—RELA—kidney cancer	5.24e-06	5.88e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—TP53—kidney cancer	5.21e-06	5.84e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	5.21e-06	5.84e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—TP53—kidney cancer	5.21e-06	5.84e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—IL2—kidney cancer	5.19e-06	5.82e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—IL2—kidney cancer	5.18e-06	5.81e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—TP53—kidney cancer	5.17e-06	5.8e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CCND1—kidney cancer	5.14e-06	5.77e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MTOR—kidney cancer	5.14e-06	5.77e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—JUN—kidney cancer	5.13e-06	5.75e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—VEGFA—kidney cancer	5.11e-06	5.73e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CTNNB1—kidney cancer	5.09e-06	5.71e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—VEGFA—kidney cancer	5.08e-06	5.7e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CCND1—kidney cancer	5.06e-06	5.67e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—JUN—kidney cancer	5.05e-06	5.66e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CCND1—kidney cancer	5.05e-06	5.66e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—JUN—kidney cancer	5.04e-06	5.65e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CTNNB1—kidney cancer	5.01e-06	5.62e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—GSTP1—kidney cancer	5.01e-06	5.62e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MAPK3—kidney cancer	5e-06	5.61e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CTNNB1—kidney cancer	5e-06	5.61e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PTEN—kidney cancer	4.98e-06	5.59e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—KRAS—kidney cancer	4.98e-06	5.58e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—POMC—kidney cancer	4.98e-06	5.58e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—PTEN—kidney cancer	4.96e-06	5.57e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—VEGFA—kidney cancer	4.94e-06	5.54e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—PIK3CA—kidney cancer	4.92e-06	5.51e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—PTEN—kidney cancer	4.88e-06	5.48e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—PTEN—kidney cancer	4.87e-06	5.46e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MYC—kidney cancer	4.87e-06	5.46e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MAPK3—kidney cancer	4.83e-06	5.42e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	4.83e-06	5.41e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MAPK3—kidney cancer	4.81e-06	5.39e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MAPK1—kidney cancer	4.76e-06	5.34e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—TP53—kidney cancer	4.76e-06	5.33e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—ABCB1—kidney cancer	4.74e-06	5.32e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—IL2—kidney cancer	4.72e-06	5.29e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MYC—kidney cancer	4.7e-06	5.27e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MAPK3—kidney cancer	4.68e-06	5.24e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MYC—kidney cancer	4.67e-06	5.24e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.65e-06	5.21e-05	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—PIK3CA—kidney cancer	4.62e-06	5.17e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—GSTM1—kidney cancer	4.61e-06	5.16e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CCND1—kidney cancer	4.6e-06	5.16e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MAPK1—kidney cancer	4.6e-06	5.15e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—JUN—kidney cancer	4.59e-06	5.15e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—PIK3CA—kidney cancer	4.58e-06	5.13e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MAPK1—kidney cancer	4.57e-06	5.13e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	4.56e-06	5.11e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MYC—kidney cancer	4.55e-06	5.1e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—KRAS—kidney cancer	4.5e-06	5.04e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—VEGFA—kidney cancer	4.48e-06	5.03e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MAPK1—kidney cancer	4.45e-06	4.99e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PTEN—kidney cancer	4.44e-06	4.98e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—TP53—kidney cancer	4.43e-06	4.96e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—VEGFA—kidney cancer	4.41e-06	4.95e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—VEGFA—kidney cancer	4.4e-06	4.94e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—CYP1A1—kidney cancer	4.37e-06	4.89e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—KRAS—kidney cancer	4.34e-06	4.87e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—KRAS—kidney cancer	4.32e-06	4.84e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MAPK3—kidney cancer	4.24e-06	4.76e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—POMC—kidney cancer	4.22e-06	4.73e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—KRAS—kidney cancer	4.2e-06	4.71e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MAPK3—kidney cancer	4.17e-06	4.68e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MAPK3—kidney cancer	4.16e-06	4.67e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—PIK3CA—kidney cancer	4.13e-06	4.63e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MYC—kidney cancer	4.13e-06	4.62e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MYC—kidney cancer	4.06e-06	4.55e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MYC—kidney cancer	4.05e-06	4.54e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MAPK1—kidney cancer	4.04e-06	4.52e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	4.01e-06	4.5e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—TP53—kidney cancer	4e-06	4.48e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—PIK3CA—kidney cancer	3.99e-06	4.47e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MAPK1—kidney cancer	3.97e-06	4.45e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PTGS2—kidney cancer	3.97e-06	4.45e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	3.97e-06	4.45e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MAPK1—kidney cancer	3.96e-06	4.44e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—PIK3CA—kidney cancer	3.86e-06	4.33e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—TP53—kidney cancer	3.86e-06	4.33e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—TP53—kidney cancer	3.84e-06	4.3e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—KRAS—kidney cancer	3.81e-06	4.27e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	3.8e-06	4.26e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—KRAS—kidney cancer	3.75e-06	4.2e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—PIK3CA—kidney cancer	3.75e-06	4.2e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—KRAS—kidney cancer	3.74e-06	4.2e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—TP53—kidney cancer	3.73e-06	4.19e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MYC—kidney cancer	3.69e-06	4.14e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	3.61e-06	4.05e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PIK3CA—kidney cancer	3.52e-06	3.94e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—PIK3CA—kidney cancer	3.5e-06	3.93e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PTEN—kidney cancer	3.46e-06	3.88e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—PIK3CA—kidney cancer	3.45e-06	3.86e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—PIK3CA—kidney cancer	3.44e-06	3.85e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—KRAS—kidney cancer	3.41e-06	3.83e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—TP53—kidney cancer	3.39e-06	3.8e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PTGS2—kidney cancer	3.36e-06	3.77e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—TP53—kidney cancer	3.33e-06	3.74e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—TP53—kidney cancer	3.33e-06	3.73e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—POMC—kidney cancer	3.26e-06	3.65e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	3.14e-06	3.51e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—TP53—kidney cancer	3.03e-06	3.4e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PTEN—kidney cancer	2.93e-06	3.29e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PTGS2—kidney cancer	2.6e-06	2.91e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CA—kidney cancer	2.44e-06	2.74e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PTEN—kidney cancer	2.26e-06	2.54e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CA—kidney cancer	2.07e-06	2.32e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.6e-06	1.79e-05	CbGpPWpGaD
